ClinicalTrials.gg
CompletedNCT03219333EV-201Updated Aug 27, 2024Results posted

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

A Phase 2 interventional study of Enfortumab vedotin in Carcinoma, Transitional Cell, Urinary Bladder Neoplasms and Urologic Neoplasms, sponsored by Astellas Pharma Inc. Completed at 81 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
219
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell — 10 open to participants now, 15 under way, 1 of them phase 3. enfortumab vedotin · Carcinoma, Transitional Cell.

Enrollment
4th of 20
219 · median 49
Started
2017
with 2 others
Phase 2
10 of 20
6 open now
Registered
2nd of 20
by date
Lead sponsor
2 of 20
Astellas Pharma Inc

Among the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 10 in phase 2, and was the 2nd registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

10 of the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About enfortumab vedotin

enfortumab vedotin: first FDA approval 2019 (PADCEV), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spread to nearby tissues or to other areas of the body.

This clinical trial will enroll patients who were previously treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI). Some CPIs have been approved for the treatment of urothelial cancer.

This study will test if the cancer shrinks with treatment. This study will also look at the side effects of the drug. A side effect is a response to a drug that is not part of the treatment effect.

Patients who sign up for this trial must also fall into one of these categories:

  • Patients have already received treatment with platinum-containing chemotherapy
  • Patients have never received platinum-containing treatment and are not eligible for treatment with cisplatin.
Read the detailed description

Japan Pharmaceuticals and Medical Devices Agency (PMDA) has approved enfortumab vedotin (Padcev) for the treatment of advanced urothelial cancer. The study will continue as a post marketing study in Japan.

This study will examine the safety and anticancer activity of enfortumab vedotin given intravenously to patients with locally advanced or metastatic urothelial cancer who previously received a CPI and either previously received platinum-containing chemotherapy (Cohort 1) or are platinum-naïve and cisplatin-ineligible (Cohort 2). Patients who received platinum in the adjuvant/neoadjuvant setting and did not progress within 12 months of completion will be considered platinum-naïve. Approximately 100 patients are expected to be enrolled in each cohort. The primary goal of the study is to determine the confirmed ORR of enfortumab vedotin.

03

Conditions studied

  • Carcinoma, Transitional Cell
  • Urinary Bladder Neoplasms
  • Urologic Neoplasms
  • Renal Pelvis Neoplasms
  • Urothelial Cancer
  • Ureteral Neoplasms
  • Urethral Neoplasms

Keywords

  • Enfortumab vedotin
  • Metastatic Urothelial Cancer
  • ASG-22CE
  • Locally Advanced Urothelial Cancer
  • Antibody-Drug Conjugate
  • Nectin-4
  • Platinum-naïve
  • Cisplatin-ineligible
  • Antineoplastic Agents
  • Drug Therapy
  • ASG-22ME
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented urothelial carcinoma (squamous differentiation or mixed cell types allowed).
  • disease or locally advanced disease that is not resectable.
  • Must have received prior treatment with a CPI in the locally advanced or metastatic urothelial cancer setting. A CPI is defined as a programmed cell death protein 1 () or programmed death-ligand 1 (PD-L1) inhibitor. Patients who received CPI therapy in the /adjuvant setting and had recurrent or progressive disease either during therapy or within 3 months of therapy completion are eligible.
  • Must either have prior treatment with platinum-containing chemotherapy (Cohort 1) or be platinum-naïve and ineligible for treatment with cisplatin at time of enrollment (Cohort 2).
  • Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.
  • Tumor tissue samples must be available for submission to the sponsor prior to study treatment.
  • Must have according to (RECIST) (Version 1.1).
  • An (ECOG) Performance Status score of ≤1 for Cohort 1 or ≤2 for Cohort 2.
  • Anticipated of ≥3 months as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Ongoing sensory or motor neuropathy Grade ≥2.
  • Active central nervous system (CNS) .
  • Immunotherapy related myocarditis, colitis, uveitis, or pneumonitis.
  • Prior enrollment in an enfortumab vedotin study or prior treatment with other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).
  • Uncontrolled tumor-related pain or impending spinal cord compression.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Enfortumab vedotin

    Enfortumab vedotin on days 1, 8 and 15 every 28 days

    Drug: Enfortumab vedotin

Interventions

  • Intravenous (IV) infusion on days 1, 8 and 15 every 28 days

    Also known as: ASG-22CE, ASG-22ME

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)

    ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)

Secondary outcomes

  1. Duration of Objective Response (DOR) Per BICR

    The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or to death due to any cause, whichever comes first. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. DOR was analyzed using Kaplan-Meier methodology.

    Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)

  2. Progression-Free Survival (PFS) Per BICR

    The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.

    Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)

  3. ORR Per Investigator Assessment

    ORR was defined as the percentage of participants with confirmed CR or PR according to RECIST 1.1. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)

  4. DOR Per Investigator Assessment

    CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.

    Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)

  5. PFS Per Investigator Assessment

    The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.

    Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)

  6. Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology)

    A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based on National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

    Time frame: The median duration of treatment was 4.60 months for Cohort 1 [range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [range: 0.3, 24.6 months]

  7. Number of Participants With Treatment-Emergent Laboratory Abnormalities (Serum Chemistry)

    A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based NCI CTCAE version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

    Time frame: The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]

  8. Incidence of Antitherapeutic Antibody (ATA)

    Participants who were tested positive for ATA at any time post-baseline were considered to be transiently positive or persistently positive if \>=2 consecutive samples were confirmed as positive.

    Time frame: The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]

  9. Disease Control Rate at 16 Weeks (DCR16) Per BICR

    Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Up to Week 16

  10. DCR16 Per Investigator Assessment

    Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Up to Week 16

  11. Overall Survival (OS): Primary Analysis

    OS is defined as the time from first dose of enfortumab vedotin to death from any cause.

    Time frame: Cohort 1 median follow-up time: 28.4 months [range 0.49, 32.62]; Cohort 2 median follow up time: 13.4 months [range 0.33 to 29.27]

  12. Number of Participants With Adverse Events (AEs): Primary Analysis

    AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event (TEAE)=newly occurring/worsening AE after first dose of study treatment, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator.

    Time frame: The median duration of treatment was 4.60 months for Cohort 1 [range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [range: 0.3, 24.6 months]

  13. Pharmacokinetics (PK) Parameter for Enfortumab Vedotin: Maximum Concentration (Cmax) (Serum)

    Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

    Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22

  14. PK Parameter for Enfortumab Vedotin: Time to Maximum Concentration (Tmax) (Serum)

    Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

    Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22

  15. PK Parameter for Enfortumab Vedotin: Area Under Concentration-Time Curve (AUC) (Serum)

    AUC was derived from the PK blood samples collected.

    Time frame: AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)

  16. PK Parameter for Free Monomethyl Auristatin E (MMAE): Cmax (Plasma)

    Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

    Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22

  17. PK Parameter for Free MMAE: Tmax (Plasma)

    Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

    Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22

  18. PK Parameter for Free MMAE: AUC (Plasma)

    AUC was derived from the PK blood samples collected.

    Time frame: AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)

  19. PK Parameter for Total Antibody (TAb): Cmax (Serum)

    Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

    Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22

  20. PK Parameter for TAb: Tmax (Serum)

    Tmax was derived from the PK blood samples collected. Time of maximum concentration corresponds to the end of infusion sample time. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

    Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22

  21. PK Parameter for TAb: AUC (Serum)

    AUC was derived from the PK blood samples collected.

    Time frame: AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)

  22. Number of Participants With Adverse Events (AEs): Final Analysis

    AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event (TEAE)=newly occurring/worsening AE after first dose of study treatment, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator.

    Time frame: Cohort 1: median treatment duration time: 4.60 months (range 0.5, 43.0); Cohort 2: median treatment duration time: 5.98 months (range 0.3 to 25.8)

  23. Overall Survival (OS): Final Analysis

    OS is defined as the time from first dose of enfortumab vedotin to death from any cause.

    Time frame: Cohort 1: median follow-up: 61.0 months (range 59.63, 62.36); Cohort 2: median follow-up time: 45.8 months (range 44.91 to 48.95)

07

Results

Posted Dec 17, 2021

Participant flow

Participant flow — Overall Study
MilestoneEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Started12891
Treated12589
Completed00
Not completed12891
Withdrew: Withdrawal by subject94
Withdrew: Lost to follow-up11
Withdrew: Death10472
Withdrew: Study closed in 2023,as all milestones reached, majority of participants completed 5 years follow-up1212
Withdrew: Other22

Outcome measures

PrimaryObjective Response Rate (ORR) Per Blinded Independent Central Review (BICR)

ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)
Percentage of ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)44 (35.1 to 53.2)51.7 (40.8 to 62.4)
SecondaryDuration of Objective Response (DOR) Per BICR

The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or to death due to any cause, whichever comes first. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. DOR was analyzed using Kaplan-Meier methodology.

Time frame:
Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Reported as:
Median · Months
Duration of Objective Response (DOR) Per BICR
MonthsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Duration of Objective Response (DOR) Per BICR7.6 (6.34 to NA)10.9 (5.78 to NA)
SecondaryProgression-Free Survival (PFS) Per BICR

The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.

Time frame:
Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Reported as:
Median · Months
Progression-Free Survival (PFS) Per BICR
MonthsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Progression-Free Survival (PFS) Per BICR5.8 (4.93 to 7.46)5.8 (5.03 to 8.28)
SecondaryORR Per Investigator Assessment

ORR was defined as the percentage of participants with confirmed CR or PR according to RECIST 1.1. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Reported as:
Number · Percentage of Participants
ORR Per Investigator Assessment
Percentage of ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
ORR Per Investigator Assessment39 (30.6 to 48.3)50.6 (39.8 to 61.3)
SecondaryDOR Per Investigator Assessment

CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.

Time frame:
Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Reported as:
Median · Months
DOR Per Investigator Assessment
MonthsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
DOR Per Investigator Assessment7.9 (5.95 to NA)10.7 (5.85 to 16.59)
SecondaryPFS Per Investigator Assessment

The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.

Time frame:
Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Reported as:
Median · Months
PFS Per Investigator Assessment
MonthsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
PFS Per Investigator Assessment5.8 (4.93 to 7.46)7.2 (5.42 to 7.69)
SecondaryNumber of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology)

A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based on National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

Time frame:
The median duration of treatment was 4.60 months for Cohort 1 [range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [range: 0.3, 24.6 months]
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology)
ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Hemoglobin decreased (all grades)5239
Hemoglobin decreased (grade 3-4)124
Leukocytes decreased (all grades)3328
Leukocytes decreased (grade 3-4)54
Lymphocytes decreased (all grades)5561
Lymphocytes decreased (grade 3-4)1213
Lymphocytes increased (all grades)01
Lymphocytes increased (grade 3-4)00
Neutrophils decreased (all grades)2827
Neutrophils decreased (grade 3-4)78
Platelets decreased (all grades)3920
Platelets decreased (grade 3-4)00
SecondaryNumber of Participants With Treatment-Emergent Laboratory Abnormalities (Serum Chemistry)

A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based NCI CTCAE version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

Time frame:
The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Serum Chemistry)
ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Alanine aminotransferase increased (all grades)3426
Alanine aminotransferase increased (grade 3-4)10
Albumin decreased (all grades)3816
Albumin decreased (grade 3-4)10
Alkaline phosphatase increased (all grades)2112
Alkaline phosphatase increased (grade 3-4)10
Aspartate aminotransferase increased (all grades)7952
Aspartate aminotransferase increased (grade 3-4)32
Bilirubin increased (all grades)135
Bilirubin increased (grade 3-4)10
Calcium decreased (all grades)157
Calcium decreased (grade 3-4)00
Calcium increased (all grades)17
Calcium increased (grade 3-4)03
Creatinine increased (all grades)7346
Creatinine increased (grade 3-4)23
Glucose decreased (all grades)3226
Glucose decreased (grade 3-4)00
Glucose increased (all grades)NANA
Glucose increased (grade 3-4)1011
Phosphate decreased (all grades)4222
Phosphate decreased (grade 3-4)126
Potassium decreased (all grades)2511
Potassium decreased (grade 3-4)21
Potassium increased (all grades)1317
Potassium increased (grade 3-4)05
Sodium decreased (all grades)5428
Sodium decreased (grade 3-4)106
Sodium increased (all grades)21
Sodium increased (grade 3-4)00
Urate increased (all grades)3238
Urate increased (grade 3-4)88
Amylase increased (all grades)2018
Amylase increased (grade 3-4)13
Lipase increased (all grades)3732
Lipase increased (grade 3-4)1210
SecondaryIncidence of Antitherapeutic Antibody (ATA)

Participants who were tested positive for ATA at any time post-baseline were considered to be transiently positive or persistently positive if \>=2 consecutive samples were confirmed as positive.

Time frame:
The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]
Reported as:
Count of participants · Participants
Incidence of Antitherapeutic Antibody (ATA)
ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Baseline Negative — Negative post-baseline10976
Baseline Negative — Transiently positive post-baseline23
Baseline Negative — Persistently positive post-baseline11
Baseline Positive — Negative post-baseline11
Baseline Positive — Transiently positive post-baseline10
Baseline Positive — Persistently positive post-baseline00
SecondaryDisease Control Rate at 16 Weeks (DCR16) Per BICR

Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Up to Week 16
Reported as:
Number · Percentage of Participants
Disease Control Rate at 16 Weeks (DCR16) Per BICR
Percentage of ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Disease Control Rate at 16 Weeks (DCR16) Per BICR50 (41.3 to 59.5)58.4 (47.5 to 68.8)
SecondaryDCR16 Per Investigator Assessment

Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Up to Week 16
Reported as:
Number · Percentage of Participants
DCR16 Per Investigator Assessment
Percentage of ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
DCR16 Per Investigator Assessment55 (46.0 to 64.1)64.0 (53.2 to 73.9)
SecondaryOverall Survival (OS): Primary Analysis

OS is defined as the time from first dose of enfortumab vedotin to death from any cause.

Time frame:
Cohort 1 median follow-up time: 28.4 months [range 0.49, 32.62]; Cohort 2 median follow up time: 13.4 months [range 0.33 to 29.27]
Reported as:
Median · Months
Overall Survival (OS): Primary Analysis
MonthsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Overall Survival (OS): Primary Analysis12.4 (9.46 to 15.57)14.7 (10.51 to 18.20)
SecondaryNumber of Participants With Adverse Events (AEs): Primary Analysis

AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event (TEAE)=newly occurring/worsening AE after first dose of study treatment, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator.

Time frame:
The median duration of treatment was 4.60 months for Cohort 1 [range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [range: 0.3, 24.6 months]
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs): Primary Analysis
ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Any treatment-emergent AEs (TEAEs)12589
Treatment-related TEAEs11786
Any grade 3-5 TEAEs9362
Treatment-related grade 3-5 TEAEs7049
Any serious TEAEs5935
Treatment-related serious TEAEs2415
Any TEAEs leading to treatment discontinuation2118
Treatment-related TEAEs leading to treatment discontinuation1514
Any TEAEs leading to death78
Treatment-related TEAEs leading to death03
SecondaryPharmacokinetics (PK) Parameter for Enfortumab Vedotin: Maximum Concentration (Cmax) (Serum)

Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

Time frame:
Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
Reported as:
Geometric mean · Microgram per milliliter (µg/mL)
Pharmacokinetics (PK) Parameter for Enfortumab Vedotin: Maximum Concentration (Cmax) (Serum)
Microgram per milliliter (µg/mL)Enfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Cycle 1, Day 126.6 ± 28.523.9 ± 24.4
Cycle 1, Day 1526.0 ± 28.321.7 ± 29.7
Cycle 2, Day 124.5 ± 31.422.0 ± 24.5
Cycle 2, Day 1526.3 ± 25.220.7 ± 27.4
SecondaryPK Parameter for Enfortumab Vedotin: Time to Maximum Concentration (Tmax) (Serum)

Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

Time frame:
Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
Reported as:
Median · Days
PK Parameter for Enfortumab Vedotin: Time to Maximum Concentration (Tmax) (Serum)
DaysEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Cycle 1, Day 10.0278 (0.010 to 0.052)0.0264 (0.021 to 0.088)
Cycle 1, Day 150.0285 (0.014 to 0.054)0.0264 (0.014 to 0.084)
Cycle 2, Day 10.0264 (0.011 to 0.042)0.0264 (0.015 to 0.074)
Cycle 2, Day 150.0285 (0.020 to 0.115)0.0257 (0.010 to 0.047)
SecondaryPK Parameter for Enfortumab Vedotin: Area Under Concentration-Time Curve (AUC) (Serum)

AUC was derived from the PK blood samples collected.

Time frame:
AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
Reported as:
Geometric mean · Day*microgram per milliliter
PK Parameter for Enfortumab Vedotin: Area Under Concentration-Time Curve (AUC) (Serum)
Day*microgram per milliliterEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 134.6 ± 34.033.5 ± 41.4
AUC(d0-7) - Cycle 1, Day 831.3 ± 43.826.3 ± 46.0
AUC(d0-7) - Cycle 2, Day 136.4 ± 36.732.0 ± 30.0
AUC(d0-7) - Cycle 2, Day 835.9 ± 41.227.8 ± 35.8
14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 834.7 ± 44.730.9 ± 47.5
AUC(d0-14) - Cycle 2, Day 1541.2 ± 40.433.1 ± 36.6
SecondaryPK Parameter for Free Monomethyl Auristatin E (MMAE): Cmax (Plasma)

Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

Time frame:
Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
Reported as:
Geometric mean · Nanogram per milliliter
PK Parameter for Free Monomethyl Auristatin E (MMAE): Cmax (Plasma)
Nanogram per milliliterEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Cycle 1, Day 13.1 ± 67.02.6 ± 57.8
Cycle 1, Day 153.9 ± 64.83.5 ± 51.8
Cycle 2, Day 12.4 ± 57.42.2 ± 60.8
Cycle 2, Day 153.0 ± 64.82.9 ± 59.9
SecondaryPK Parameter for Free MMAE: Tmax (Plasma)

Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

Time frame:
Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
Reported as:
Median · Days
PK Parameter for Free MMAE: Tmax (Plasma)
DaysEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Cycle 1, Day 11.9 (1 to 5)1.9 (1 to 4)
Cycle 1, Day 152.0 (1 to 11)1.9 (1 to 9)
Cycle 2, Day 12.0 (1 to 5)1.8 (1 to 5)
Cycle 2, Day 151.9 (1 to 9)1.9 (1 to 10)
SecondaryPK Parameter for Free MMAE: AUC (Plasma)

AUC was derived from the PK blood samples collected.

Time frame:
AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
Reported as:
Geometric mean · Day*nanogram per milliliter
PK Parameter for Free MMAE: AUC (Plasma)
Day*nanogram per milliliterEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 114.1 ± 81.713.0 ± 64.1
AUC(d0-7) - Cycle 1, Day 819.1 ± 79.118.1 ± 65.0
AUC(d0-7) - Cycle 2, Day 111.3 ± 58.010.6 ± 65.0
AUC(d0-7) - Cycle 2, Day 814.9 ± 64.715.3 ± 60.2
14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 1525.9 ± 74.722.6 ± 76.4
AUC(d0-14) - Cycle 2, Day 1519.1 ± 61.221.3 ± 65.0
SecondaryPK Parameter for Total Antibody (TAb): Cmax (Serum)

Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

Time frame:
Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
Reported as:
Geometric mean · Microgram per milliliter
PK Parameter for Total Antibody (TAb): Cmax (Serum)
Microgram per milliliterEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Cycle 1, Day 126.6 ± 30.426.4 ± 23.4
Cycle 1, Day 1530.9 ± 22.927.3 ± 25.7
Cycle 2, Day 126.2 ± 30.526.3 ± 23.8
Cycle 2, Day 1530.2 ± 22.727.1 ± 28.2
SecondaryPK Parameter for TAb: Tmax (Serum)

Tmax was derived from the PK blood samples collected. Time of maximum concentration corresponds to the end of infusion sample time. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.

Time frame:
Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
Reported as:
Median · Days
PK Parameter for TAb: Tmax (Serum)
DaysEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Cycle 1, Day 10.0278 (0.010 to 0.052)0.0264 (0.021 to 0.088)
Cycle 1, Day 150.0285 (0.014 to 0.054)0.0264 (0.014 to 0.084)
Cycle 2, Day 10.0264 (0.011 to 0.042)0.0264 (0.015 to 0.074)
Cycle 2, Day 150.0285 (0.020 to 0.115)0.0257 (0.010 to 0.047)
SecondaryPK Parameter for TAb: AUC (Serum)

AUC was derived from the PK blood samples collected.

Time frame:
AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
Reported as:
Geometric mean · Day*microgram per milliliter
PK Parameter for TAb: AUC (Serum)
Day*microgram per milliliterEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 163.4 ± 33.666.8 ± 34.3
AUC(d0-7) - Cycle 1, Day 877.6 ± 35.272.3 ± 37.9
AUC(d0-7) - Cycle 2, Day 173.2 ± 33.572.9 ± 26.4
AUC(d0-7) - Cycle 2, Day 887.9 ± 30.681.0 ± 30.9
14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 1598.1 ± 38.891.1 ± 40.3
AUC(d0-14) - Cycle 2, Day 15113.0 ± 33.8109.7 ± 41.5
SecondaryNumber of Participants With Adverse Events (AEs): Final Analysis

AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event (TEAE)=newly occurring/worsening AE after first dose of study treatment, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator.

Time frame:
Cohort 1: median treatment duration time: 4.60 months (range 0.5, 43.0); Cohort 2: median treatment duration time: 5.98 months (range 0.3 to 25.8)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs): Final Analysis
ParticipantsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Any treatment-emergent AEs (TEAEs)12589
Treatment-related TEAEs11786
Any grade 3-5 TEAEs9362
Treatment-related grade 3-5 TEAEs7049
Any serious TEAEs5935
Treatment-related serious TEAEs2415
Any TEAEs leading to treatment discontinuation2221
Treatment-related TEAEs leading to treatment discontinuation1617
Any TEAEs leading to death78
Treatment-related TEAEs leading to death03
SecondaryOverall Survival (OS): Final Analysis

OS is defined as the time from first dose of enfortumab vedotin to death from any cause.

Time frame:
Cohort 1: median follow-up: 61.0 months (range 59.63, 62.36); Cohort 2: median follow-up time: 45.8 months (range 44.91 to 48.95)
Reported as:
Median · Months
Overall Survival (OS): Final Analysis
MonthsEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Overall Survival (OS): Final Analysis12.4 (9.46 to 15.57)15.6 (11.24 to 20.37)

Adverse events

Collected over Cohort 1: maximum up to 62.36 months of follow-up; Cohort 2: maximum up to 48.95 months of follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enfortumab Vedotin - Cohort 1104/125 (83.2%)59/125 (47.2%)123/125 (98.4%)
Enfortumab Vedotin - Cohort 272/89 (80.9%)35/89 (39.3%)88/89 (98.9%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
Acute kidney injuryRenal and urinary disorders4/1259/89
CellulitisInfections and infestations6/1250/89
Urinary tract infectionInfections and infestations6/1253/89
SepsisInfections and infestations4/1254/89
Febrile neutropeniaBlood and lymphatic system disorders5/1251/89
DiarrhoeaGastrointestinal disorders3/1253/89
PneumoniaInfections and infestations3/1253/89
Transitional cell carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1253/89
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1250/89
Abdominal painGastrointestinal disorders3/1251/89
Most frequent other events
Showing 10 of 80
Most frequent other events
EventEnfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2
AlopeciaSkin and subcutaneous tissue disorders64/12548/89
Peripheral sensory neuropathyNervous system disorders54/12547/89
FatigueGeneral disorders66/12540/89
Decreased appetiteMetabolism and nutrition disorders64/12535/89
NauseaGastrointestinal disorders56/12526/89
DiarrhoeaGastrointestinal disorders52/12530/89
DysgeusiaNervous system disorders49/12527/89
AnaemiaBlood and lymphatic system disorders44/12534/89
Weight decreasedInvestigations40/12531/89
PruritusSkin and subcutaneous tissue disorders34/12531/89

Baseline characteristics

Safety population included all participants who received any amount of enfortumab vedotin.

Age, Continuous
Age, Continuous(Years)Enfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2Total
Median69.0 (40 to 84)75.0 (49 to 90)72.0 (40 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)Enfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2Total
Female372360
Male8866154
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2Total
Hispanic or Latino516
Not Hispanic or Latino11883201
Unknown or Not Reported257
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2Total
American Indian or Alaska Native000
Asian112031
Native Hawaiian or Other Pacific Islander000
Black or African American202
White10662168
More than one race000
Unknown or Not Reported6713
Region of Enrollment
Region of Enrollment(Participants)Enfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2Total
North America11757174
Europe01414
East Asia81826
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Enfortumab Vedotin - Cohort 1Enfortumab Vedotin - Cohort 2Total
0403777
18541126
201111
08

Study locations

81 sites
  • Alaska Urological Institute
    Anchorage, Alaska 99503, United States
  • Arizona Oncology Associates, PC - HAL
    Goodyear, Arizona 85395, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85710, United States
  • Keck Medical Center / University of Southern California
    Los Angeles, California 90033, United States
  • Keck Medical Center / Newport Beach
    Newport Beach, California 92663, United States
  • Kaiser Permanente Oakland
    Oakland, California 94611, United States
  • Chao Family Comprehensive Cancer Center University of California Irvine
    Orange, California 92868, United States
  • University of California Irvine - Newport
    Orange, California 92868, United States
  • Kaiser Permanente Roseville
    Roseville, California 95661, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • Kaiser Permanente Sacramento
    Sacramento, California 95825, United States
  • Kaiser Permanente San Francisco
    San Francisco, California 94115, United States
  • Kaiser Permanente San Jose
    San Jose, California 95119, United States
  • Kaiser Permanente San Leandro
    San Leandro, California 94577, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Kaiser Permanente South San Francisco
    South San Francisco, California 94080, United States
  • Kaiser Permanente Medical Center Northern California
    Vallejo, California 94589, United States
  • Kaiser Permanente Walnut Creek
    Walnut Creek, California 94596, United States
  • Rocky Mountain Cancer Centers - Aurora
    Aurora, Colorado 80012, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637-1470, United States
  • Norton Cancer Institute, St. Matthews Campus
    Louisville, Kentucky 40207, United States
  • Johns Hopkins Medical Center
    Baltimore, Maryland 21231, United States
  • Maryland Oncology Hematology, P.A.
    Rockville, Maryland 20850, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Washington University in St Louis
    Saint Louis, Missouri 63110, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12208, United States
  • New York University (NYU) Cancer Institute
    New York, New York 10016, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • James P. Wilmot Cancer Center / University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • James Cancer Hospital / Ohio State University
    Columbus, Ohio 43210, United States
  • Northwest Cancer Specialists, P.C.
    Tigard, Oregon 97223, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Prisma Health
    Greenville, South Carolina 29615, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
  • Texas Oncology - Austin Central
    Austin, Texas 78731, United States
  • Texas Oncology - Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Seattle Cancer Care Alliance / University of Washington
    Seattle, Washington 98109-1023, United States
  • Site FR33001
    Villejuif-Cedex-France, France
  • Site DE49004
    Muenster, Germany
  • Site DE49001
    Tübingen, Germany
  • Site IT39001
    Milano, Italy
  • Site IT39003
    Terni, Italy
  • Site JP81001
    Hirosaki, Aomori, Japan
  • Site JP81004
    Tsukuba, Ibaraki, Japan
  • Site JP81002
    Morioka, Iwate, Japan
  • Site JP81008
    Osakasayama, Osaka, Japan
  • Site JP81006
    Shinjuku-ku, Tokyo, Japan
  • Site JP81009
    Ube, Yamaguchi, Japan
  • Site JP81005
    Chiba, Japan
  • Site JP81011
    Fukuoka, Japan
  • Site JP81012
    Fukuoka, Japan
  • Site JP81003
    Nigata, Japan
  • Site JP81007
    Osaka, Japan
  • Site JP81010
    Tokushima, Japan
  • Site KR82005
    Daejeon, Korea, Republic of
  • Site KR82003
    Seongnam-si, Korea, Republic of
  • Site KR82001
    Seoul, Korea, Republic of
  • Site KR82002
    Seoul, Korea, Republic of
  • Site KR82004
    Seoul, Korea, Republic of
  • Site NL31001
    Amsterdam, Netherlands
  • Site ES34002
    Barcelona, Spain
  • Site ES34005
    Barcelona, Spain
  • Site ES34003
    Santander, Spain
  • Site ES34004
    Sevilla, Spain
09

References and documents

Publications

  • McGregor B, O'Donnell PH, Balar A, Petrylak D, Rosenberg J, Yu EY, Quinn DI, Heath EI, Campbell M, Hepp Z, McKay C, Steinberg J, Regnault A, Mazerolle F, Galsky MD. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. Eur Urol. 2022 May;81(5):515-522. doi: 10.1016/j.eururo.2022.01.032. Epub 2022 Feb 12. PubMed 35168844 ↗
  • Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Erratum In: Lancet Oncol. 2021 Jun;22(6):e239. doi: 10.1016/S1470-2045(21)00300-4. PubMed 33991512 ↗
  • Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29. PubMed 31356140 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Oct 2020, 36 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2017
First posted
Jul 17, 2017
StartActual
Oct 8, 2017
Primary completionActual
Oct 27, 2020
CompletionActual
Jul 28, 2023
Results first posted
Dec 17, 2021
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03219333
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Jul 17, 2017
Start date
Oct 8, 2017
Primary completion
Oct 27, 2020
Completion
Jul 28, 2023
Results posted
Dec 17, 2021
Last update
Aug 27, 2024

Study contacts

Janet Trowbridge, MD, PhD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enfortumab vedotin

Start the discussion